{"name":"Kedrion Biopharma","slug":"kedrion","ticker":"Private","exchange":"N/A","domain":"kedrion.com","description":"Kedrion Biopharma is a private company specializing in plasma-derived therapies and biologics. The company focuses on developing and manufacturing products for the treatment of rare and serious diseases. Kedrion Biopharma's key products include clotting factor concentrates and immunoglobulins. As a private company, Kedrion Biopharma's financial information is not publicly disclosed.","hq":"Barga, Tuscany, Italy","founded":0,"employees":"","ceo":"Ugo Di Francesco","sector":"Plasma-Derived Therapies / Biologics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$3.5B (est. private valuation)","metrics":{"revenue":1900000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Berinert patent cliff ($100M at risk)","drug":"Berinert","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Hizentra patent cliff ($500M at risk)","drug":"Hizentra","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2022-09-01","type":"deal","headline":"Kedrion Biopharma Acquires BioLife Plasma Services","summary":"Kedrion Biopharma acquired BioLife Plasma Services, expanding its plasma collection network.","drugName":"","sentiment":"positive"},{"date":"2020-02-14","type":"regulatory","headline":"FDA Approves Kedrion's Berinert for Hereditary Angioedema","summary":"The FDA approved Berinert, a C1 esterase inhibitor, for the treatment of hereditary angioedema.","drugName":"Berinert","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQaVNMa0k4THFRQTQ0MHp1YTZGSzBEUDdHbzFld3hlUGJ6SG42Z1ZPWUJuaXdQVERVbkd3Q2dwOU13anFUR3VGRzBvSW90Y3NWNm4wQXN2NXRMMXRlUzctQWF1ZEVoeEl3T2xhRS03bzg3RUcyYUpfMmtMNngzaFBqRmxheXBYWkpQQlNQQS1SVXFkaGdOVjJuXzZMa01HeEtoc2pIWmhIeV9FdUlTRjFxVExTbmotaVltN1FacXJzV2gtbFRaLWFPV3h1N2JiNG9SZ3Zqd3pibFR4TThXdloxSW9lVGU5dXlRbUZ0U2NYdkhYTXFGb1hv?oc=5","date":"2026-03-13","type":"pipeline","source":"Business Wire","summary":"AOM Infusion Selected as a Limited Distribution Specialty Pharmacy for QIVIGY®, A New Immune Globulin Therapy - Business Wire","headline":"AOM Infusion Selected as a Limited Distribution Specialty Pharmacy for QIVIGY®, A New Immune Globulin Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOWTBTS3N2aFpYckNSeGFLMjFtOHd5T0liZmh5SS10OThEMFAwaDhWMmpkRkRrZThFMTd4bFIzNTVJdlh1U3FXcE9uN3l0VXlYb3IxM1pERHY1ZFo1cGxGVFFlYVpEOEtDTkRFSnZHYzNPc1F5djNlUzVTbFQ5M3VYSDAxVGdpb2wwU3FSRWF2ZDBBN3RrYUJPTThaRQ?oc=5","date":"2026-01-15","type":"pipeline","source":"Capital Analytics Associates","summary":"Biopharma innovation surges as regulation and risk rise - Capital Analytics Associates","headline":"Biopharma innovation surges as regulation and risk rise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPUU1SRTdTdzgtdW1Ndk9FdVA5X2NvUUlEQmhnNm5fVjBUdjdnTnFtaTRkZGFwTkZKUUo4TFhKMHM2Qm9xQ3B4Umt0Y0lGa1BJekZLeDlrTnpBc05FbzU0eVJWUDF2WTh3MXZkR2NBVjhMY0JOYmJMaGU0TXV4b0JpSGd0VzkwWlduWjQwXzNMY2IxNjVEVTRCVjVCZEJKQVlRSk1pQjZNcFpqREx0Q0dTaEhQb1RkMjFlOTBjeWVHRGp4SUtXaTJXVVo4OUVvMWplUlE4V2xDSEZrS0h3RnhocHB4dk4ya002d0x4OGszVURocWxHR3h5cXRqS21mX2VwRkNwa3ZNbGs?oc=5","date":"2025-12-02","type":"pipeline","source":"Business Wire","summary":"AOM Infusion Designated a Limited Distribution Network Specialty Pharmacy for YIMMUGO® Immunoglobulin Replacement Therapy - Business Wire","headline":"AOM Infusion Designated a Limited Distribution Network Specialty Pharmacy for YIMMUGO® Immunoglobulin Replacement Therap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOUFJ4Rm0xcU1DXzdRQmFmb2RXZzlFMVFCTmxOUk1yR0I5bV9tQVh5Y1AzRE55QTlJeF83eDdWc3E1clViSDVYMmVpTWViUDUtMkU4SzNEZm9wWXhROVNWVkRSM1Z5MHRTQzRibEdyS25DTmxBTlc1OE9lT1ZQa0dlMTdCaTc5ZTlxTEE?oc=5","date":"2025-04-14","type":"pipeline","source":"Yahoo Finance","summary":"Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity - Yahoo Finance","headline":"Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUDJmbHlUeUNqTHJ3R3lPZ0ZLQjJhSFkyRHY0M0h5cEdOU3lyZDJPaHFNUkJmV0hNTEFrR3hUaG9xU1dlam5ETnRrYXVtZFBuYWc1Nm1YWEZOMGFzZjdzd2NHWGpaRVZBTTI2b3VVeEhUekxReEhUcktzQXJBMjhKRFZ5dnRwS3dLMjZ5azRYbkhpcG44aUlQYnM2S1Ricm1tQno1TDVaQWYtQzl1X1F5bWdEajUzeUJpcFJpTXUwYmFDWXM?oc=5","date":"2024-11-20","type":"pipeline","source":"Fierce Pharma","summary":"Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer - Fierce Pharma","headline":"Plasma specialist Grifols shrugs off private equity firm Brookfield's potential €6.5B takeover offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQRTZ0dVhNWUF1bm1iRFMzZ3ZrVnJrUXhaQXdESmZBWnlZeGlSMnQzOVFOUmF3Tkd4dTQ5NmxMX2VoSmwwUWJDTGQ0cGV1dnk0NG1DTHdIQmRXblRKajVDUkFVQklhSE8ybXpXNm1pTFd5ODNEak5WdEVYLWNOVjBtYmJSanlSaEptTnNlSkRmdGFGdks4bGs1cA?oc=5","date":"2024-06-06","type":"pipeline","source":"citybiz","summary":"Permira Announces Substantial Investment in PharmaCord - citybiz","headline":"Permira Announces Substantial Investment in PharmaCord","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPWnJwd01sNmZlcVpuTHJwb1hvSzVnOVVkWVpDSFZCSUdGZzQwQlVWellVRzJ0cmYxQ1VpamdjeGFkUmF2ZUo4aEZHUFpRSWVoTlE1SUFzVU85VFk3Y0o5LWM5UWtRb0NuVWRWMnEwdGVYT1A2NVJxbDlrTkRxb01GbmFBM0huU09CbDVKbVZOMWRGeDNsYnBR?oc=5","date":"2023-04-10","type":"deal","source":"Bain & Company","summary":"Biopharma: Healthcare Private Equity Scores a Record Year in Deal Value - Bain & Company","headline":"Biopharma: Healthcare Private Equity Scores a Record Year in Deal Value - Bain & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxONWRnbXgzU1Z6Z0V3STZzRUkxWUVaLUxaczJGLTA4SEpSMHVQZ1BFNk9QWXI4SGk3VmVSQlFXc2FLbjJ5c0xDY0tLb05FdVJDV1hxbjBUaDE1Z1R2cjdSUDFibWlCY2duX1dmZC1oYm5iNTVXQ0VrcGQ3Z3BZSGE3UUZfUU5aYjBRNXgyMm9BY18tdlhOSFVaZFVzZmZKWHAxOUZJWVZLVjdCXzFhaUlWRjBROHdURnVlbjNWTjhxeTVlX09pRHhhWm5IUmh5b1ZCUUdnd3V5WkR0ejRVNnR0dXRhR2g4RndRdDdpMGdGU1JrTnpIZTZwdDlRdFhUenZlRE9uNWV5ZVlteTN0Yk1HV1h3?oc=5","date":"2022-09-01","type":"pipeline","source":"PR Newswire","summary":"Permira Funds and the Marcucci family complete investment in Kedrion and BPL and announce appointment of Ugo Di Francesco as CEO - PR Newswire","headline":"Permira Funds and the Marcucci family complete investment in Kedrion and BPL and announce appointment of Ugo Di Francesc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNZWZBbnphNmdDUXk4SFRrUXlXUm9VdXJPR1hrS0haaWpsVjYwSUlWZlVxYnA4ci1ZcURmTlppSEVHb3drc1ZhRWZWUVBjSzlleFh5RWtwQzd3ZGVTdEplQ1FDc2xLRF9lWTNTZnNCX3RVWUQ4UXIzQjgySDIzelM4aERYbGlfZEduc3ZxcmNJZnVXZU9WLS1aOW96cFRSYUUwb1NWUm5XUjB1Zi0xRlhUSw?oc=5","date":"2022-01-20","type":"deal","source":"Bloomberg.com","summary":"Private Equity Firm Permira Is Making a Big Bet on Blood Plasma With New Deals - Bloomberg.com","headline":"Private Equity Firm Permira Is Making a Big Bet on Blood Plasma With New Deals","sentiment":"neutral"}],"patents":[{"drugName":"Berinert","drugSlug":"c1-esterase-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":100000000},{"drugName":"Hizentra","drugSlug":"immunoglobulin","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":500000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Baxter International","Grifols","Bioverativ"],"therapeuticFocus":["Hemostasis","Immunology"],"financials":null,"yahoo":null}